Matthew Caufield

Q: What is Matthew Caufield's success rate?

Matthew Caufield currently has a success rate of 91.70649028315208.

Q: What is the average return of Matthew Caufield's calls?

Their stock ratings have generated an average return of 36.011488697418045.

HC Wainwright & Co. | Healthcare

Matthew Caufield is an analyst from HC Wainwright & Co. specializing in the Healthcare sector. Ranked #570 out of 4773 analysts, they have issued 47 stock ratings with a success rate of 91.71% and an average return of 36.01%.

Matthew Caufield has a well-established track record, with 47 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 91.71% and an average return of 36.01%, underscoring their expertise and ability to identify winning opportunities for investors.

#570

Out of 4773

Total Ratings

+91.71%

Success Rate

+36.01%

Average Return

Recent Ratings Analysis

IRD

Buy

Sep 09, 2026

Target

$8.00

Current

$6.04

Performance

5.41%

Matthew Caufield rated IRD as Buy on Sep 09, 2026, setting a price target of 8. The call has proven timely, with shares rising 5.41% toward the price target of 8.

FBLG

Buy

Aug 04, 2026

Target

$6.00

Current

$1.61

Performance

95.86%

On Aug 04, 2026, FBLG was given a Buy rating by Matthew Caufield, with a target price of 6. The stock rallied 95.86% after the rating, narrowing the gap to the target of 6 and validating the bullish stance.

PHAT

Buy

Jul 31, 2026

Target

$26.00

Current

$8.36

Performance

-4.46%

PHAT received a Buy rating from Matthew Caufield on Jul 31, 2026, aiming for 26. Price action was muted, as shares hovered around 8.36 despite the bullish outlook.

FDMT

Buy

Jul 20, 2026

Target

$36.00

Current

$13.17

Performance

18.76%

On Jul 20, 2026, Matthew Caufield published a Buy outlook on FDMT, with a target of 36. Shares gained 18.76%, underscoring the accuracy of the bullish outlook toward 36.

TARS

Buy

Jul 09, 2026

Target

$88.00

Current

$79.31

Performance

23.65%

Matthew Caufield on Jul 09, 2026 assigned TARS a Buy rating, with a price target of 88. The Buy call aligned well with market performance, producing a gain of 23.65%.

LENZ

Buy

Jul 07, 2026

Target

$38.00

Current

$4.52

Performance

-23.39%

On Jul 07, 2026, Matthew Caufield reaffirmed LENZ with a Buy rating, targeting 38. Shares slid 23.39% despite the recommendation, highlighting downside risks.

AKBA

Buy

Jul 01, 2026

Target

$6.00

Current

$0.95

Performance

-21.35%

AKBA was rated Buy by Matthew Caufield on Jul 01, 2026, with a price objective of 6. This case shows how bullish projections can fail, with the stock now below 0.9517.

UPB

Buy

Jun 03, 2026

Target

$36.00

Current

$5.73

Performance

-24.90%

On Jun 03, 2026, Matthew Caufield initiated coverage on UPB with a Buy rating and target of 36. The Buy call has yet to be validated as shares remain 30.27 away from the target.

ZBIO

Buy

May 15, 2026

Target

$44.00

Current

$31.12

Performance

69.68%

Matthew Caufield issued a Buy recommendation for ZBIO on May 15, 2026, price target set at 44. Investors following the Buy call captured upside momentum, with shares now at 31.12.

SRZN

Buy

May 07, 2026

Target

$44.00

Current

$19.00

Performance

-38.21%

On May 07, 2026, SRZN was evaluated by Matthew Caufield, who gave a Buy rating and target of 44. Investors saw limited payoff as shares fell short of the 44 target.

IMUX

Buy

Apr 30, 2026

Target

$22.00

Current

$11.42

Performance

18.71%

Matthew Caufield rated IMUX as Buy on Apr 30, 2026, setting a price target of 22. The call has proven timely, with shares rising 18.71% toward the price target of 22.

KOD

Buy

Mar 27, 2026

Target

$58.00

Current

$32.89

Performance

-11.11%

On Mar 27, 2026, KOD was given a Buy rating by Matthew Caufield, with a target price of 58. Despite the Buy call, shares fell from 32.89 to 32.89, challenging the optimistic stance.

ALDX

Hold

Mar 18, 2026

Target

$2.00

Current

$1.34

Performance

-5.63%

ALDX received a Neutral rating from Matthew Caufield on Mar 18, 2026, aiming for 2. The Hold stance proved prudent, with the market softening by 5.63%.

ARDX

Buy

Feb 20, 2026

Target

$18.00

Current

$3.58

Performance

-37.52%

On Feb 20, 2026, Matthew Caufield published a Buy outlook on ARDX, with a target of 18. Market action contradicted the Buy thesis, as shares slipped to 3.58.

ADVM

Hold

Nov 17, 2025

Target

$5.00

Current

$4.36

Performance

2.11%

Matthew Caufield on Nov 17, 2025 assigned ADVM a Neutral rating, with a price target of 5. The Hold stance reflected consolidation, as shares held near 4.36.

MLYS

Buy

Nov 12, 2025

Target

$56.00

Current

$28.20

Performance

-40.42%

On Nov 12, 2025, Matthew Caufield reaffirmed MLYS with a Buy rating, targeting 56. Shares slid 40.42% despite the recommendation, highlighting downside risks.

DMAC

Buy

Aug 15, 2025

Target

$12.00

Current

$6.47

Performance

7.30%

DMAC was rated Buy by Matthew Caufield on Aug 15, 2025, with a price objective of 12. A bullish response from the market helped close the gap of 5.53 to the target.

LYRA

Hold

Aug 14, 2025

Target

$16.00

Current

$0.20

Performance

-97.18%

On Aug 14, 2025, Matthew Caufield initiated coverage on LYRA with a Neutral rating and target of 16. The rating matched the stock’s inability to hold above 0.2.

HLVX

Hold

Mar 31, 2025

Target

$2.00

Current

$2.09

Performance

44.14%

Matthew Caufield issued a Neutral recommendation for HLVX on Mar 31, 2025, price target set at 2. A neutral call gave way to stronger-than-expected performance, closing in on 2.

UBX

Buy

Mar 25, 2025

Target

$4.00

Current

$0.20

Performance

-84.12%

On Mar 25, 2025, UBX was evaluated by Matthew Caufield, who gave a Buy rating and target of 4. Investors saw limited payoff as shares fell short of the 4 target.

OPT

Hold

Mar 25, 2025

Target

$2.00

Current

$3.41

Performance

0.00%

Matthew Caufield rated OPT as Neutral on Mar 25, 2025, setting a price target of 2. The Hold stance appears justified, as shares hovered around 3.41 with a 0.00% move.

EYEN

Hold

Mar 21, 2025

Target

$2.00

Current

$7.56

Performance

447.83%

On Mar 21, 2025, EYEN was given a Neutral rating by Matthew Caufield, with a target price of 2. The stock rallied from 7.56 to 7.56 after the Hold rating, surprising to the upside.

OPTN

Hold

Mar 21, 2025

Target

$9.00

Current

$9.60

Performance

4.92%

OPTN received a Neutral rating from Matthew Caufield on Mar 21, 2025, aiming for 9. Shares remained flat at 9.6, aligning with the neutral rating.

OCUP

Buy

Aug 15, 2024

Target

$18.00

Current

$1.17

Performance

-5.65%

On Aug 15, 2024, Matthew Caufield published a Buy outlook on OCUP, with a target of 18. Market action contradicted the Buy thesis, as shares slipped to 1.17.

Frequency Asked Questions

Who is Matthew Caufield?

Matthew Caufield is an analyst from HC Wainwright & Co. specializing in the Healthcare sector.

What is Matthew Caufield's success rate?

Matthew Caufield currently has a success rate of +91.71%.

How many ratings has Matthew Caufield issued?

Matthew Caufield has issued 47 stock ratings so far.

What is the average return of Matthew Caufield's calls?

Their stock ratings have generated an average return of +36.01%.

What is Matthew Caufield's ranking?

Matthew Caufield is ranked #570 out of 4773 analysts.

What types of ratings does Matthew Caufield give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Matthew Caufield?

You can follow Matthew Caufield by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Matthew Caufield?

Their latest rating was a Buy on IRD issued on 2026-09-09.